United Therapeutics Corp Stock Forecast for 2023 - 2025 - 2030
Updated on 11/28/2023
United Therapeutics Corp Stock Forecast and Price Target
United Therapeutics Corp's stock is projected to advance by 30.21% from the previous closing price if it reaches the average target of $300.00 by the year's end, as four reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $375.00 and a low-end estimate of $177.00. If you're looking for information on United Therapeutics Corp stock, consider checking out the forecasts for comparable firms such as NasdaqGS:REGN.
30.21% Upside
United Therapeutics Corp Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, United Therapeutics Corp's Price has grown, moving from $142.47 to $183.98 – an increase of 29.13%. In the next year, analysts predict that Fair Value will jump to $224.38 – up 21.96% from the current level. Looking ahead to eight years, experts forecast that Fair Value will grow by 20.23%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
16
|
$591.60 | Buy/Sell | $594.01 | 9.87% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$151.63 | Buy/Sell | $176.14 | 13.43% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$100.18 | Buy/Sell | $123.75 | 24.78% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$29.69 | Buy/Sell | $40.55 | 26.31% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$48.92 | Buy/Sell | $64.26 | 25.72% |
United Therapeutics Corp Revenue Forecast for 2023 - 2025 - 2030
In the last three years, United Therapeutics Corp's Revenue has grown, moving from $1.45B to $1.94B – an increase of 33.65%. In the next year, analysts predict that Revenue will jump to $2.25B – up 16.12% from the current level. Looking ahead to eight years, experts forecast that Revenue will grow by 117.71%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
15
|
$347.04 | Buy/Sell | $395.90 | 12.38% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$801.14 | Buy/Sell | $796.73 | 14.09% |
| ZTS Stock Forecast | Zoetis Inc | Outperform |
18
|
$176.97 | Buy/Sell | $217.57 | 18.66% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$161.36 | Buy/Sell | $245.24 | 42.54% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$36.34 | Buy/Sell | $45.50 | 22.45% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$9.14 | Buy/Sell | $11.74 | 25.82% |
United Therapeutics Corp Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Free Cash Flow for United Therapeutics Corp has grown by 328.63%, going from $-290.30M to $663.70M. In the coming year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $937.00M – an increase of 41.18%. Over the next eight years, experts anticipate that Free Cash Flow growth for United Therapeutics Corp will be 88.54%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals Inc | Outperform |
9
|
$48.34 | Buy/Sell | $51.20 | 24.12% |
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$39.46 | Buy/Sell | $49.29 | 21.64% |
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$30.46 | Buy/Sell | $45.67 | 44.45% |
United Therapeutics Corp Net Income Forecast for 2023 - 2025 - 2030
United Therapeutics Corp's Net Income has seen growth In the last three years, going from $-104.50M to $727.30M – a gain of 795.98% In the next year, analysts believe that Net Income will reach $1.00B – an increase of 38.14%. For the next eight years, the forecast is forNet Income to grow by 21.68%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$122.71 | Buy/Sell | $145.00 | 22.24% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$190.94 | Buy/Sell | $170.08 | 73.09% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$16.60 | Buy/Sell | $37.00 | 34.04% |
United Therapeutics Corp EBITDA Forecast for 2023 - 2025 - 2030
United Therapeutics Corp's EBITDA has grown in the last three years, jumping from $-131.70M to $1.04B – an increase of 889.90%. In the next year, analysts predict that EBITDA will reach $1.27B – an increase of 21.82%. For the next eight years, the forecast is for EBITDA to grow by 4.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CYTK Stock Forecast | Cytokinetics Inc | Outperform |
10
|
$31.22 | Buy/Sell | $61.75 | 92.18% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$54.41 | Buy/Sell | $69.00 | 21.30% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$25.45 | Buy/Sell | $0.00 | 41.45% |
United Therapeutics Corp EBIT Forecast for 2023 - 2025 - 2030
In the last three years, United Therapeutics Corp's EBIT has increased by 656.87%, going from $-177.60M to $989.00M. In the next year, analysts are expecting an increase in EBIT, predicting it will reach $1.18B – an increase of 19.14%. The United Therapeutics Corp forecast is for EBIT to reach $2.44B or grow by 147.12%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£12.38 | Buy/Sell | £3.79 | 134.25% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$12.63 | Buy/Sell | $26.83 | 90.02% |
| CPRX Stock Forecast | Catalyst Pharmaceuticals | Outperform |
16
|
$14.21 | Buy/Sell | $23.30 | 75.93% |
United Therapeutics Corp EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, United Therapeutics Corp's EPS has grown, moving from $12.94 to $16.71 – an increase of 29.13%. In the next year, analysts predict that EPS will jump to $20.38 – up 21.96% from the current level. Looking ahead to eight years, experts forecast that EPS will grow by 20.23%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Outperform |
14
|
$9.68 | Buy/Sell | $17.40 | 106.61% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$26.97 | Buy/Sell | $41.00 | 53.87% |
| ARPO Stock Forecast | Aerpio Pharmaceuticals | - |
6
|
$30.30 | Buy/Sell | $0.00 | -100.00% |
Site Navigation
.jpg)